NPs that inhibited both PD-1 and A2A genes resulted in the activation of T cells from tumor-derived or spleen-derived sources, thus secrete more pro-inflammatory cytokines interleukin-17 (IL-17) and IFN-γ and less anti-inflammatory cytokines interleukin-4 (IL-4) and IL-10 compared with NPs that inhibited PD-1 or A2A alone [100]. The gene discussed is IL17A; the disease is neoplasm.